Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFi Dose Adjustment in Stable Ankylosing Spondylitis
NCT05164198Phase 4Unknown
- Sponsor
- Hanyang University
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 4, randomised, open-label trial of adalimumab, etanercept, golimumab and infliximab in ankylosing spondylitis (AS) (2 arms), sponsored by Hanyang University. Primary endpoint: Percentage of Participants who did not experience a flare at 48 weeks. Status: unknown.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05164198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164198.